- Home
- CXM vs OCS Comparison
CXM vs OCS Comparison
Compare CXM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXM | OCS |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CXM | OCS |
|---|---|---|
| Price | $5.98 | $26.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $9.89 | ★ $41.86 |
| AVG Volume (30 Days) | ★ 2.4M | 308.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 144.44 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $796,394,000.00 | N/A |
| Revenue This Year | $8.25 | $418.43 |
| Revenue Next Year | $3.44 | $892.34 |
| P/E Ratio | $119.80 | ★ N/A |
| Revenue Growth | ★ 8.74 | N/A |
| 52 Week Low | $5.12 | $14.00 |
| 52 Week High | $9.69 | $30.68 |
Technical Indicators
Market Signals| Indicator | CXM | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 43.56 |
| Support Level | $5.19 | $25.99 |
| Resistance Level | $8.06 | $29.23 |
| Average True Range (ATR) | 0.22 | 1.04 |
| MACD | 0.11 | -0.44 |
| Stochastic Oscillator | 85.15 | 2.58 |
Price Performance
Historical ComparisonAbout CXM Sprinklr Inc.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.